NKF advises BioTelemetry, Inc. on its competing public tender offer to the shareholders of LifeWatch AG
Niederer Kraft Frey is advising BioTelemetry, Inc. on the public tender offer made by its subsidiary Cardiac Monitoring Holding Company, LLC for all publicly-held registered shares of LifeWatch AG. The transaction is a recommended competing bid in which LifeWatch shareholders are offered cash and shares of BioTelemetry common stock, with a total transaction value of approximately CHF 260 million. The transaction is expected to close in June 2017.
BioTelemetry, Inc., headquartered in Malvern, Pennsylvania, USA and listed on NASDAQ, provides monitoring services and digital population health management in a healthcare setting, medical device manufacturing, and centralized core laboratory services for clinical research. SIX listed LifeWatch AG is a leading health care services and technology company, specialized in providing remote wireless diagnostic monitoring services as well as developing and manufacturing advanced digital health systems.
The NKF team is led by Philipp Haas (partner) and Thomas M. Brönnimann (partner) and further consisted of Deirdre Ní Annracháin (associate), Julia Tolstova (associate), Samuel Hochstrasser (associate) and Alexander Göbel (junior associate, all Corporate/M&A).
NKF acted alongside Greenberg Traurig, LLP, who acts as U.S. counsel to BioTelemetry, Inc.